US firm adds Colorado boutique with biotech practice

The move marks the firm’s second western merger this year | Joining firm has a strong presence in Denver and Asia markets.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Amgen hit with lawsuit over its proposed Opdivo biosimilar

16 September 2026 BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.

Pharma

Beyond the primary patent: How pharma can build competitive barriers

16 September 2026 A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.

Biotech

Australian biotech sues Grail over multi-cancer blood test

15 September 2026 Grail is facing a patent infringement lawsuit over its Galleri cancer detection test, as Clinical Genomics seeks to enforce its intellectual property while no longer being commercially operational.

More features

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Australian biotech sues Grail over multi-cancer blood test

K&L Gates hires six-partner team of IP and corporate lawyers from Pillsbury

Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients

Built to be bought? What makes companies acquisition-ready

Patent lawyers and judges discuss lofty UPC issues in grand London venue

J&J names two-decade veteran as chief IP counsel

J&J unit win shuts door on Sandoz generic launch

US firm adds Colorado boutique with biotech practice

More on this story

Editor's picks

Editor's picks

More features